Maja de Jonge
Overview
Explore the profile of Maja de Jonge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolf J, Hochmair M, Han J, Reguart N, Souquet P, Smit E, et al.
Lancet Oncol
. 2024 Oct;
25(10):1357-1370.
PMID: 39362249
Background: Capmatinib has previously shown activity in treatment-naive and previously treated patients with non-small-cell lung cancer (NSCLC) and a MET exon 14-skipping mutation (METex14). Here, we report the final outcomes...
2.
Janku F, Kim T, Iyer G, Spreafico A, Elez E, de Jonge M, et al.
Eur J Cancer
. 2023 Dec;
196:113458.
PMID: 38039779
Background: We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations. Methods: This first-in-human phase 1 study had...
3.
Biesdorf C, Guan X, Siddani S, Hoffman D, Boehm N, Medeiros B, et al.
Cancer Chemother Pharmacol
. 2023 Nov;
93(4):329-339.
PMID: 38036720
Purpose: Eftozanermin alfa is a second-generation tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist that enhances death receptor 4/5 clustering on tumor cells to induce apoptosis. We report the pharmacokinetics...
4.
Drew Y, Kim J, Penson R, OMalley D, Parkinson C, Roxburgh P, et al.
Clin Cancer Res
. 2023 Nov;
30(1):50-62.
PMID: 37939124
Purpose: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib plus durvalumab....
5.
Krebs M, Delord J, Evans T, de Jonge M, Kim S, Meurer M, et al.
Lung Cancer
. 2023 May;
180:107216.
PMID: 37146473
Introduction: Preclinical studies have demonstrated increased efficacy with combined DNA damage response inhibition and immune checkpoint blockade compared with either alone. We assessed olaparib in combination with durvalumab in patients...
6.
Vieito M, Simonelli M, de Vos F, Moreno V, Geurts M, Lorenzi E, et al.
Neurooncol Adv
. 2022 Nov;
4(1):vdac146.
PMID: 36382109
Background: Standard-of-care treatment for newly diagnosed glioblastoma (ndGBM), consisting of surgery followed by radiotherapy (RT) and temozolomide (TMZ), has improved outcomes compared with RT alone; however, prognosis remains poor. Trotabresib,...
7.
Schoffski P, Awada A, de la Bigne A, Felloussi Z, Burbridge M, Cantero F, et al.
Eur J Cancer
. 2022 May;
169:135-145.
PMID: 35567919
Background: S81694 is an inhibitor of monopolar spindle 1 kinase, a target expressed in proliferating cells. CL1-81694-001 was the first-in-human study aiming at identifying a safe dosing schedule in solid...
8.
Rodon J, Argiles G, Connolly R, Vaishampayan U, de Jonge M, Garralda E, et al.
Br J Cancer
. 2021 May;
125(1):28-37.
PMID: 33941878
Background: This Phase 1 study assessed the safety and efficacy of the Porcupine inhibitor, WNT974, in patients with advanced solid tumours. Methods: Patients (n = 94) received oral WNT974 at...
9.
Wolf J, Seto T, Han J, Reguart N, Garon E, Groen H, et al.
N Engl J Med
. 2020 Sep;
383(10):944-957.
PMID: 32877583
Background: Among patients with non-small-cell lung cancer (NSCLC), exon 14 skipping mutations occur in 3 to 4% and amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the...
10.
de Weger V, de Jonge M, Langenberg M, Schellens J, Lolkema M, Varga A, et al.
Br J Cancer
. 2018 Dec;
120(3):286-293.
PMID: 30585255
Background: This phase I, open-label, dose-escalation study evaluated the safety, pharmacokinetics and pharmacodynamics of combination therapy with the HDM2 inhibitor SAR405838 and the MEK1/2 inhibitor pimasertib administered orally once daily...